Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2
Conditions
Interventions
210 mg brodalumab
140 mg brodalumab
+1 more
Locations
103
United States
Research Site
Peoria, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Cypress, California, United States
Research Site
Hemet, California, United States
Research Site
Huntington Beach, California, United States
Research Site
La Jolla, California, United States
Start Date
March 1, 2014
Primary Completion Date
October 1, 2015
Completion Date
October 1, 2015
Last Updated
August 20, 2020
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
NCT07315061
Lead Sponsor
Bausch Health Americas, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions